<DOC>
	<DOC>NCT00824369</DOC>
	<brief_summary>The purpose of the protocol is to assess long-term safety and tolerability of subjects who discontinue for any reason from UK-453,061 qualifying studies.</brief_summary>
	<brief_title>A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1</brief_title>
	<detailed_description>To assess long term safety and tolerability of subjects who discontinue for any reason from UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these patients. The trial was terminated prematurely on January 29, 2013, due to the decision of the sponsor to discontinue development of lersivirine. The decision to terminate the trial was not based on any safety or efficacy concerns.</detailed_description>
	<criteria>Previous participation in a qualifying study. Male or female at least 18 years of age available for a followup period of at least 96 weeks. Concurrent treatment in another clinical trial. Unwilling or unable to be followed for 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Rollover</keyword>
	<keyword>Safety.</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>treatment experienced</keyword>
</DOC>